About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:3814367
Allelic
Composition
ApcMin/Apc+
Brca2tm1Mbn/Brca2+
Genetic
Background
B6.Cg-Brca2tm1Mbn ApcMin
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
ApcMin mutation (8 available); any Apc mutation (90 available)
Brca2tm1Mbn mutation (0 available); any Brca2 mutation (62 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
N
• body weight of mice at time of sacrifice does not differ significantly from Apc-heterozygous, Brca2-heterozygous, or wild-type animals

reproductive system
N
• only observed in 1/8 ENU-treated males, similar to wild-type males (1/9)
• absent in 22% of ENU-treated females
• remaining follicles are degenerating in ENU-treated females
• arrested follicular development is 6-fold more prevalent compared to ENU-treated Brca2-deficient mice
• complete loss of follicles (ovarian atrophy) is observed in about 25% of ENU-treated mutants, whereas almost no incidence is observed in ENU-treated wild-type or Brca2-mutant females
• observed in ENU-treated females displaying ovarian failure (atrophy); endometrium and myometrium appear immature
• reduced in thickness and lined with vacuolated cells indicative of anestrus in ENU-treated females

neoplasm
• by 65 days after ENU treatment, 100% of females develop mammary tumors with a multiplicity of 7.2 +/- 2.7, whereas only 7% of wild-type females develop tumors
• males develop tumors at a very low incidence and with a tumor multiplicity of 0.2 +/- 0.3, whereas no wild-type or Brca2-heterozygous males developed mammary tumors
• tumors in male and female mice are adenoacanthomas, characterized by undifferentiated acini and tubules with centrally confined squamous cells and keratin; most tumors contain proportions of adenomatous and squamous cell types
• tumors with predominantly squamous differentiation, moderate to marked inflammation in and around tumors is observed, with areas of fibrosis; in some cases, squamous component becomes cystic and is filled with keratinous debris
• invasion or metastases into the mammary lymph nodes was not observed during time course of study
• multiple intestinal tumors are observed in ENU-treated mice

endocrine/exocrine glands
• in ENU treated mice, male mammary ducts are elongated and in most males have extended to the lymph node of the fourth mammary gland, whereas wild-type and Brca2-heterozygous males are born with a small mammary gland rudiment, which grows no further, and no nipple
• no differences are observed in branching of female mammary glands among genotypes or wild-type females
• by 65 days after ENU treatment, 100% of females develop mammary tumors with a multiplicity of 7.2 +/- 2.7, whereas only 7% of wild-type females develop tumors
• males develop tumors at a very low incidence and with a tumor multiplicity of 0.2 +/- 0.3, whereas no wild-type or Brca2-heterozygous males developed mammary tumors
• tumors in male and female mice are adenoacanthomas, characterized by undifferentiated acini and tubules with centrally confined squamous cells and keratin; most tumors contain proportions of adenomatous and squamous cell types
• tumors with predominantly squamous differentiation, moderate to marked inflammation in and around tumors is observed, with areas of fibrosis; in some cases, squamous component becomes cystic and is filled with keratinous debris
• invasion or metastases into the mammary lymph nodes was not observed during time course of study
• absent in 22% of ENU-treated females
• remaining follicles are degenerating in ENU-treated females
• arrested follicular development is 6-fold more prevalent compared to ENU-treated Brca2-deficient mice
• complete loss of follicles (ovarian atrophy) is observed in about 25% of ENU-treated mutants, whereas almost no incidence is observed in ENU-treated wild-type or Brca2-mutant females

homeostasis/metabolism

integument
• in ENU treated mice, male mammary ducts are elongated and in most males have extended to the lymph node of the fourth mammary gland, whereas wild-type and Brca2-heterozygous males are born with a small mammary gland rudiment, which grows no further, and no nipple
• no differences are observed in branching of female mammary glands among genotypes or wild-type females
• by 65 days after ENU treatment, 100% of females develop mammary tumors with a multiplicity of 7.2 +/- 2.7, whereas only 7% of wild-type females develop tumors
• males develop tumors at a very low incidence and with a tumor multiplicity of 0.2 +/- 0.3, whereas no wild-type or Brca2-heterozygous males developed mammary tumors
• tumors in male and female mice are adenoacanthomas, characterized by undifferentiated acini and tubules with centrally confined squamous cells and keratin; most tumors contain proportions of adenomatous and squamous cell types
• tumors with predominantly squamous differentiation, moderate to marked inflammation in and around tumors is observed, with areas of fibrosis; in some cases, squamous component becomes cystic and is filled with keratinous debris
• invasion or metastases into the mammary lymph nodes was not observed during time course of study

Mouse Models of Human Disease
OMIM ID Ref(s)
Breast Cancer 114480 J:67445


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
08/17/2016
MGI 6.05
The Jackson Laboratory